Eli Lilly Designs P-Tau Biomarker Assay for Early Alzheimer’s Disease Diagnosis
The Pharma Data
NOVEMBER 10, 2020
“They will help researchers mechanistically assess target engagement in clinical trials,” and also will be used in clinical practice to identify the right drugs for the right patients, Howard Fillet, M.D., Importantly, “It demonstrated a lack of drug interference for each drug studied,” Dage said. ADNI trial.
52 
Let's personalize your content